Arvinas Inc. ARVN
$7.37
▲ +6.91% 24H
About
Arvinas Inc. is a clinical-stage biotechnology company focused on discovering, developing, and advancing proteolysis targeting chimeras (PROTAC) targeted protein degraders. These innovative therapies harness the body's natural protein disposal system to selectively degrade and remove disease-causing proteins, enabling …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees246
TickerARVN
Statistics
Market Cap$475.5M
Revenue (TTM)$262.6M
Net Income-$80.8M
Net Margin-30.8%
EPS$-1.14
P/E-6.64
P/S5.12
P/B1.18
EV/EBITDA0.63
ROE-42.3%
Dividend Yield—
Price$7.37
Data: Twelve Data · Revenue = mcap / P/S